Pharmafile

Abcuro, a company specializing in musculoskeletal disorders, has recently completed enrollment for its MUSCLE registration phase 2/3 clinical trial. This trial is focused on evaluating the effectiveness of ulviprubart (ABC008) in treating inclusion body myositis (IBM), a rare and debilitating condition with no current treatment options. The trial is a global, randomized, double-blind, placebo-controlled study … Read more